Sequana Medical announces first-in-human data of Direct Sodium Removal (DSR) therapy published in Circulation

Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for treatment of volume overload due to heart failure

Ghent, Belgium: 10 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the results of the pre-clinical and first-in-human single dose DSR proof-of-concept studies for volume overload due to heart failure have been published in the prestigious peer-reviewed journal Circulation1. The publication can be accessed here. The studies, conducted by Dr. Jeffrey Testani of Yale University, demonstrated that single dose DSR therapy was safe and well-tolerated and resulted in a clinically relevant removal of sodium. Volume overload is the driver of more than 90% of the one million heart failure hospitalisations in the U.S. each year (which in total account for $13 billion in costs). Re-hospitalisation is common and approximately 24% of these patients are re-admitted within 30 days of discharge. Sequana Medical’s innovative DSR therapy removes sodium from the body, which in turn eliminates the associated fluid to restore sodium concentration, resulting in sustained fluid removal. More info on Sequana's website